Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray in 6–11 Year Old Patients With Seasonal Allergic Rhinitis
2017-003856-22Phase 3
- Sponsor
- Alcon Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in seasonal allergic rhinitis (SAR) comparing Olopatadine HCl Nasal Spray 0.6% with Nasal Spray Vehicle (2 arms). Primary endpoint: Percent Change from Baseline in rTNSS.
02
Drugs
olopatadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2017-003856-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003856-22.